Farshid Dayyani

University of California, Irvine

United States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Collaborators (6)

Nadine Abi-Jaoudeh

University of California, Irvine

UNITED STATES

Roozbeh Houshyar

University of California

UNITED STATES

Heide, Aurelia Stirnadel-Farrant

Tumor Head, Oncology Outcomes Research

AstraZeneca UK Limited

UNITED KINGDOM

Gregory Botta

Associate Clinical Professor

University of California, San Diego

UNITED STATES

Maheswari Senthil

Professor of Surgery

University of California, Irvine

UNITED STATES

Garrett Harada

Assistant Professor

University of California, Irvine

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Farshid Dayyani

Research Interests

Explore related searches

Contact this professor

Articles (20)

Collaborators (6)

Nadine Abi-Jaoudeh

Roozbeh Houshyar

Heide, Aurelia Stirnadel-Farrant

Gregory Botta

Maheswari Senthil

Garrett Harada

Make your next move.

Farshid Dayyani

Research Interests

Explore related searches

Contact this professor

Articles (20)

Treatment Patterns and Outcomes in Patients with Advanced Biliary Tract Cancers Treated with Gemcitabine-Based Chemotherapy: A Retrospective Study

Ethnic Demographic Shifts and the Rise in Early-Onset Esophageal, Gastric, and Colorectal Malignancies in the United States

A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors

Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors

Beginning at the End? Rethinking the Timing of Enrollment Into Early Phase Clinical Trials

Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells

Modulation of Tumor-Associated Macrophages to Overcome Immune Suppression in the Hepatocellular Carcinoma Microenvironment

Associations between language, telehealth, and clinical outcomes in patients with cancer during the COVID‐19 pandemic

A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors

The Impact of Local Control on Overall Survival after Y-90 Selective Internal Radiotherapy of Liver Metastases in Oligometastatic Cancer: A Retrospective Analysis

Exosomes as a Source of Biomarkers for Gastrointestinal Cancers

Durable Response after Repeat Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Extensive Mucinous Adenocarcinoma of the Appendix

Targeting Hypoxia-Inducible Factor-1α for the Management of Hepatocellular Carcinoma

Rapid and Deep Response to Lorlatinib in Pancreatic High-Grade Neuroendocrine Carcinoma With a Treatment Emergent Novel KANK1-ALK Fusion

Spontaneous Fluctuations of Tumor-Informed Circulating Tumor DNA at Low Levels

A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE)

Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers

Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma

A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen

A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC)

Collaborators (6)

Nadine Abi-Jaoudeh

Roozbeh Houshyar

Heide, Aurelia Stirnadel-Farrant

Gregory Botta

Maheswari Senthil

Garrett Harada

Make your next move.